Karyopharm Therapeutics (KPTI) Competitors $4.39 -0.04 (-0.90%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$4.39 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. LXEO, IKT, ALEC, EPRX, BDTX, KRRO, FTLF, NKTX, GLSI, and TARAShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Korro Bio (KRRO), FitLife Brands (FTLF), Nkarta (NKTX), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Lexeo Therapeutics Inhibikase Therapeutics Alector Eupraxia Pharmaceuticals Black Diamond Therapeutics Korro Bio FitLife Brands Nkarta Greenwich LifeSciences Protara Therapeutics Lexeo Therapeutics (NASDAQ:LXEO) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, institutional ownership, media sentiment, valuation and risk. Is LXEO or KPTI more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Lexeo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lexeo TherapeuticsN/A -57.66% -48.18% Karyopharm Therapeutics -52.62%N/A -39.58% Which has more risk & volatility, LXEO or KPTI? Lexeo Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Do institutionals & insiders believe in LXEO or KPTI? 60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 5.3% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 3.0% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher valuation and earnings, LXEO or KPTI? Lexeo Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexeo Therapeutics$650K230.34-$66.39M-$3.30-1.37Karyopharm Therapeutics$142.13M0.27-$143.10M-$13.26-0.33 Does the media refer more to LXEO or KPTI? In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 1.77 beat Karyopharm Therapeutics' score of 0.94 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor LXEO or KPTI? Karyopharm Therapeutics received 515 more outperform votes than Lexeo Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 72.44% of users gave Karyopharm Therapeutics an outperform vote. CompanyUnderperformOutperformLexeo TherapeuticsOutperform Votes29100.00% Underperform VotesNo VotesKaryopharm TherapeuticsOutperform Votes54472.44% Underperform Votes20727.56% Do analysts prefer LXEO or KPTI? Lexeo Therapeutics currently has a consensus target price of $18.50, indicating a potential upside of 310.20%. Karyopharm Therapeutics has a consensus target price of $43.20, indicating a potential upside of 884.05%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Lexeo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryLexeo Therapeutics beats Karyopharm Therapeutics on 12 of the 18 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$38.28M$6.85B$5.57B$8.63BDividend YieldN/A2.56%5.28%4.18%P/E Ratio-4.308.7827.1220.06Price / Sales0.27255.64412.30157.10Price / CashN/A65.8538.2534.64Price / Book-2.996.557.064.70Net Income-$143.10M$143.93M$3.23B$247.88M7 Day Performance3.05%3.84%2.86%2.63%1 Month Performance-28.62%11.20%9.07%6.36%1 Year Performance-71.59%4.18%31.45%14.05% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics4.0347 of 5 stars$4.39-0.9%$43.20+884.1%-71.0%$38.28M$142.13M-4.30380LXEOLexeo Therapeutics3.5467 of 5 stars$4.38+12.9%$18.50+322.4%-74.3%$145.40M$650K-1.3958Positive NewsIKTInhibikase Therapeutics1.4975 of 5 stars$1.95-0.5%$6.50+233.3%+22.9%$144.97M$260K-0.736Positive NewsALECAlector3.5174 of 5 stars$1.44-3.4%$4.00+177.8%-63.1%$143.99M$88.34M-0.85270Positive NewsShort Interest ↑Analyst RevisionEPRXEupraxia Pharmaceuticals2.2996 of 5 stars$3.97+0.8%$10.50+164.5%+38.9%$142.32MN/A-5.5129BDTXBlack Diamond Therapeutics3.4677 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690KRROKorro Bio3.5683 of 5 stars$14.85+1.8%$102.43+589.8%-64.8%$139.46M$4.82M-1.5770Positive NewsAnalyst RevisionFTLFFitLife Brands4.1971 of 5 stars$14.19-0.8%$20.50+44.5%-5.9%$133.26M$63.86M16.7920Positive NewsShort Interest ↑NKTXNkarta3.667 of 5 stars$1.87-1.6%$14.67+684.3%-69.2%$132.69MN/A-0.99140Analyst ForecastGLSIGreenwich LifeSciences2.2745 of 5 stars$9.45-2.2%$39.00+312.7%-32.1%$126.33MN/A-11.813TARAProtara Therapeutics2.4871 of 5 stars$3.27-2.1%$20.50+526.9%+20.1%$126.16MN/A-1.1630Positive NewsAnalyst Revision Related Companies and Tools Related Companies Lexeo Therapeutics Competitors Inhibikase Therapeutics Competitors Alector Competitors Eupraxia Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Korro Bio Competitors FitLife Brands Competitors Nkarta Competitors Greenwich LifeSciences Competitors Protara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
